With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
Venture capital has the brains, private equity has the books – can they make lots of money?
The gloomy climate for biotech is now taking its toll on private companies too.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.